17:36 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Leukodystrophy Cell culture, worm and mouse studies suggest inhibiting HDAC6 and other HDACs could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated with defects in autophagy, neurogenesis and neuronal...
07:00 , Sep 1, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Variants in a panel of 72 genes as risk markers for sarcoma

Biomarkers TECHNOLOGY: Gene profiling Variants in multiple genes associated with other cancers could help predict the risk of sarcoma. In blood and serum samples from three independent cohorts totaling 1,162 sarcoma patients and 6,545 healthy...
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Brain-derived neurotrophic factor (BDNF); neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2); excision repair cross-complementation group 6 (ER

Neurology INDICATION: Leukodystrophy Patient sample and cell studies suggest BDNF , BDNF mimetics or other agonists of its receptor, TrkB , could help treat Cockayne syndrome, a leukodystrophy caused by ERCC6 mutations that is associated...
07:00 , Sep 4, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Excision repair cross-complementation group 2 (ERCC2) mutations as a predictive marker of cisplatin sensitivity in urothelial carcinomas Studies in patient samples and cell culture suggest loss-of-function...